First Tracks Biotherapeutics (HAM:B43) Common Stock: €0.00 Mil (As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Common Stock?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 Common Stock is €0.00 Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Common Stock Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Common Stock
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Common Stock 0.00 0.00
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.00 Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Common Stock of €0.00 Mil as of Dec. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Common Stock too high?
First Tracks Biotherapeutics' current Common Stock is €0.00 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Common Stock compare to ALT and RGNX?
First Tracks Biotherapeutics' Common Stock of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Common Stock is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Common Stock of €0.00 Mil. The current Common Stock is €0.00 Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Common Stock is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price